Traders purchased shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on weakness during trading hours on Thursday. $106.28 million flowed into the stock on the tick-up and $57.91 million flowed out of the stock on the tick-down, for a money net flow of $48.37 million into the stock. Of all equities tracked, Alexion Pharmaceuticals had the 2nd highest net in-flow for the day. Alexion Pharmaceuticals traded down ($0.49) for the day and closed at $122.71
A number of research firms have recently commented on ALXN. Evercore ISI raised Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a report on Monday, February 5th. Citigroup lowered their price objective on Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating on the stock in a research report on Friday, February 9th. Leerink Swann lowered their price objective on Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. BMO Capital Markets increased their price objective on Alexion Pharmaceuticals from $177.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, February 9th. Finally, SunTrust Banks set a $172.00 price objective on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, February 12th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty-one have assigned a buy rating to the company. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $152.77.
The company has a current ratio of 3.10, a quick ratio of 2.62 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $27,202.53, a PE ratio of 61.46, a price-to-earnings-growth ratio of 1.14 and a beta of 1.16.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The business had revenue of $909.70 million for the quarter, compared to the consensus estimate of $880.38 million. During the same quarter last year, the business posted $1.26 earnings per share. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. analysts expect that Alexion Pharmaceuticals, Inc. will post 6.12 earnings per share for the current year.
In other Alexion Pharmaceuticals news, SVP Heidi L. Wagner sold 655 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $117.26, for a total transaction of $76,805.30. Following the sale, the senior vice president now owns 32,635 shares in the company, valued at $3,826,780.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Paul J. Clancy sold 6,079 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $116.31, for a total value of $707,048.49. Following the sale, the chief financial officer now owns 95,093 shares in the company, valued at approximately $11,060,266.83. The disclosure for this sale can be found here. Insiders have sold 28,930 shares of company stock worth $3,378,199 in the last 90 days. Company insiders own 4.35% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALXN. Delpha Capital Management LLC purchased a new position in shares of Alexion Pharmaceuticals in the fourth quarter worth about $102,000. Valeo Financial Advisors LLC purchased a new position in shares of Alexion Pharmaceuticals in the third quarter worth about $147,000. Dupont Capital Management Corp purchased a new position in shares of Alexion Pharmaceuticals in the third quarter worth about $156,000. BT Investment Management Ltd purchased a new position in shares of Alexion Pharmaceuticals in the third quarter worth about $165,000. Finally, Beacon Investment Advisory Services Inc. purchased a new position in shares of Alexion Pharmaceuticals in the third quarter worth about $201,000. Institutional investors and hedge funds own 94.01% of the company’s stock.
WARNING: “Investors Buy Shares of Alexion Pharmaceuticals (ALXN) on Weakness” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.thelincolnianonline.com/2018/02/17/investors-buy-shares-of-alexion-pharmaceuticals-alxn-on-weakness.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.